<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Crit Care</journal-id><journal-title-group><journal-title>Critical Care</journal-title></journal-title-group><issn pub-type="ppub">1364-8535</issn><issn pub-type="epub">1466-609X</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19735585</article-id><article-id pub-id-type="pmc">2784342</article-id><article-id pub-id-type="publisher-id">cc8013</article-id><article-id pub-id-type="doi">10.1186/cc8013</article-id><article-categories><subj-group subj-group-type="heading"><subject>Commentary</subject></subj-group></article-categories><title-group><article-title>Oropharyngeal decontamination in intensive care patients: less is not more</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Derde</surname><given-names>Lennie PG</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lderde@umcutrecht.nl</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Bonten</surname><given-names>Marc JM</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>mbonten@umcutrecht.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Julius Center for Health Sciences and Primary Care, Heidelberglaan 100, Location Stratenum, 3584 CX Utrecht, The Netherlands</aff><aff id="I2"><label>2</label>Department of Medical Microbiology, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands</aff><pub-date pub-type="ppub"><year>2009</year></pub-date><pub-date pub-type="epub"><day>3</day><month>9</month><year>2009</year></pub-date><volume>13</volume><issue>5</issue><fpage>183</fpage><lpage>183</lpage><permissions><copyright-statement>Copyright Â©2009 BioMed Central Ltd</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>BioMed Central Ltd</copyright-holder></permissions><self-uri xlink:href="http://ccforum.com/content/13/5/183"></self-uri><abstract><p><offsets xml_i="2219" xml_f="2719" txt_i="11" txt_f="511">Ventilator-associated pneumonia (VAP) is a common cause of morbidity, antibiotic use, increased length of stay and, possibly, increased mortality in ICU patients. Colonization of the oropharyngeal cavity with potentially pathogenic micro-organisms is instrumental in the pathogenesis of VAP, and selective oropharyngeal decontamination (SOD) with antibiotics (AB-SOD) or antiseptics, such as chlorhexidine gluconate (CHX-SOD), has been associated with reduced incidences of VAP. In a recent issue of </offsets><italic><offsets xml_i="2727" xml_f="2741" txt_i="511" txt_f="525">Critical Care </offsets></italic><offsets xml_i="2750" xml_f="3023" txt_i="525" txt_f="798">Scannapieco and colleagues investigated differences in oropharyngeal colonization between mechanically ventilated patients receiving oropharyngeal decontamination with 0.12% CHX-SOD either once or twice daily compared to placebo. CHX-SOD was associated with a reduction in </offsets><italic><offsets xml_i="3031" xml_f="3053" txt_i="798" txt_f="820">Staphylococcus aureus </offsets></italic><offsets xml_i="3062" xml_f="3287" txt_i="820" txt_f="1045">colonization, but the study was underpowered to demonstrate a reduction in VAP incidence. We urgently need well-designed and adequately powered studies to evaluate the potential benefits of CHX-SOD on patient outcome in ICUs.</offsets></p></abstract></article-meta><notes><p>See related research by Scannapieco <italic>et al.</italic>, <ext-link ext-link-type="uri" xlink:href="http://ccforum.com/content/13/4/R117">http://ccforum.com/content/13/4/R117</ext-link></p></notes></front><body><sec><title></title><p><offsets xml_i="3564" xml_f="3635" txt_i="1054" txt_f="1125">In this commentary we discuss the study of Scannapieco and colleagues [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="3666" xml_f="3667" txt_i="1125" txt_f="1126">1</offsets></xref><offsets xml_i="3674" xml_f="3707" txt_i="1126" txt_f="1159">] published in a recent issue of </offsets><italic><offsets xml_i="3715" xml_f="3728" txt_i="1159" txt_f="1172">Critical Care</offsets></italic><offsets xml_i="3737" xml_f="3738" txt_i="1172" txt_f="1173">.</offsets></p><p><offsets xml_i="3745" xml_f="3859" txt_i="1174" txt_f="1288">Ventilator-associated pneumonia (VAP) frequently occurs in ICUs, with reported incidences ranging from 9% to 27% [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="3890" xml_f="3891" txt_i="1288" txt_f="1289">2</offsets></xref><offsets xml_i="3898" xml_f="4137" txt_i="1289" txt_f="1528">]. It is a leading cause of morbidity and, possibly, of mortality. As a result, many interventions have been designed and evaluated for the prevention of VAP. One of the most successful interventions in this regard is oral decontamination.</offsets></p><p><offsets xml_i="4144" xml_f="4368" txt_i="1529" txt_f="1753">Colonization of the upper respiratory tract generally precedes the occurrence of VAP, most probably because of a reduced capacity to clear pathogens and/or an increased adherence of micro-organisms to the respiratory tract [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="4399" xml_f="4400" txt_i="1753" txt_f="1754">3</offsets></xref><offsets xml_i="4407" xml_f="4662" txt_i="1754" txt_f="2009">]. Prevention of oropharyngeal colonization has been achieved with topically applied non-absorbable antibiotics (referred to as selective oropharyngeal decontamination with antibiotics (AB-SOD)) or with topically applied chlorhexidine gluconate (CHX-SOD).</offsets></p><p><offsets xml_i="4669" xml_f="4742" txt_i="2010" txt_f="2083">AB-SOD was associated with reduced incidences of VAP in various studies [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="4773" xml_f="4774" txt_i="2083" txt_f="2084">4</offsets></xref><offsets xml_i="4781" xml_f="4782" txt_i="2084" txt_f="2085">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="4813" xml_f="4814" txt_i="2085" txt_f="2086">6</offsets></xref><offsets xml_i="4821" xml_f="4909" txt_i="2086" txt_f="2174">], and recently also with a better 28-day survival in a large Dutch multi-center study [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="4940" xml_f="4941" txt_i="2174" txt_f="2175">7</offsets></xref><offsets xml_i="4948" xml_f="5534" txt_i="2175" txt_f="2761">]. In that study, AB-SOD was equally effective in improving patient outcome as selective decontamination of the digestive tract (SDD), which combines AB-SOD with intestinal decontamination and 4 days of intravenous cefotaxim. The occurrence of resistance as a result of AB-SOD or SDD, however, remains of concern, especially in countries with endemic levels of antimicrobial-resistant bacteria (AMRB). Therefore, simply replacing antibiotics with antiseptics for oral decontamination might offer an effective and safe measure for ICU patients, even in settings with high levels of AMRB.</offsets></p><p><offsets xml_i="5541" xml_f="5622" txt_i="2762" txt_f="2843">Indeed, CHX-SOD appeared effective in reducing VAP incidence in several studies [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="5653" xml_f="5654" txt_i="2843" txt_f="2844">8</offsets></xref><offsets xml_i="5661" xml_f="5662" txt_i="2844" txt_f="2845">-</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="5694" xml_f="5696" txt_i="2845" txt_f="2847">13</offsets></xref><offsets xml_i="5703" xml_f="5949" txt_i="2847" txt_f="3093">]. However, the regimens used were not always carefully described and concentrations and dosing frequencies varied from 0.12% CHX twice daily to 2% CHX four times a day. In addition, patient populations varied widely: from mixed ICU populations [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="5980" xml_f="5981" txt_i="3093" txt_f="3094">9</offsets></xref><offsets xml_i="5988" xml_f="5989" txt_i="3094" txt_f="3095">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="6021" xml_f="6023" txt_i="3095" txt_f="3097">12</offsets></xref><offsets xml_i="6030" xml_f="6058" txt_i="3097" txt_f="3125">] to surgical ICU patients [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6090" xml_f="6092" txt_i="3125" txt_f="3127">10</offsets></xref><offsets xml_i="6099" xml_f="6142" txt_i="3127" txt_f="3170">] and patients undergoing cardiac surgery [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="6173" xml_f="6174" txt_i="3170" txt_f="3171">8</offsets></xref><offsets xml_i="6181" xml_f="6182" txt_i="3171" txt_f="3172">,</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="6214" xml_f="6216" txt_i="3172" txt_f="3174">11</offsets></xref><offsets xml_i="6223" xml_f="6224" txt_i="3174" txt_f="3175">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="6256" xml_f="6258" txt_i="3175" txt_f="3177">13</offsets></xref><offsets xml_i="6265" xml_f="6329" txt_i="3177" txt_f="3241">]. Furthermore, nasal application of CHX was used in one study [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="6361" xml_f="6363" txt_i="3241" txt_f="3243">13</offsets></xref><offsets xml_i="6370" xml_f="6420" txt_i="3243" txt_f="3293">] and CHX was combined with Colistine in another [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="6452" xml_f="6454" txt_i="3293" txt_f="3295">12</offsets></xref><offsets xml_i="6461" xml_f="6525" txt_i="3295" txt_f="3359">], and in one study effects were compared to historic controls [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6557" xml_f="6559" txt_i="3359" txt_f="3361">10</offsets></xref><offsets xml_i="6566" xml_f="7056" txt_i="3361" txt_f="3851">]. Moreover, all individual studies published so far have been underpowered to demonstrate effects of CHX-SOD on patient survival. In a recently published systematic review and meta-analysis, CHX-SOD was associated with a significant reduction in VAP incidence of 44%, although the studies were very heterogeneous, which precludes firm conclusions about its protective effects. No reductions in overall mortality, duration of mechanical ventilation or length of stay could be demonstrated [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="7087" xml_f="7088" txt_i="3851" txt_f="3852">2</offsets></xref><offsets xml_i="7095" xml_f="7097" txt_i="3852" txt_f="3854">].</offsets></p><p><offsets xml_i="7104" xml_f="7150" txt_i="3855" txt_f="3901">In their article, Scannapieco and colleagues [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7181" xml_f="7182" txt_i="3901" txt_f="3902">1</offsets></xref><offsets xml_i="7189" xml_f="7468" txt_i="3902" txt_f="4181">] aimed to determine the optimal frequency of CHX-SOD to prevent VAP in trauma ICU patients. The study contains a control group (49 patients) and two intervention groups receiving CHX 0.12% either once (47 patients) or twice daily (50 patients). They conclude that the number of </offsets><italic><offsets xml_i="7476" xml_f="7498" txt_i="4181" txt_f="4203">Staphylococcus aureus </offsets></italic><offsets xml_i="7507" xml_f="8105" txt_i="4203" txt_f="4801">in dental plaque was reduced in both intervention groups, but no significant reductions were observed in the total number of respiratory pathogens or incidence of VAP. Estimated reductions in colonization were 25% and 30% in the 'twice-daily' and 'once-daily' groups, respectively. The odds ratio for developing VAP was 0.54 (95% confidence interval 0.23 to 1.25) for patients receiving CHX-SOD, which is remarkably similar to the pooled estimate from the most recent meta-analysis. Although this may suggest a beneficial effect of CHX-SOD, it cannot be demonstrated by a study of this sample size.</offsets></p><p><offsets xml_i="8112" xml_f="8848" txt_i="4802" txt_f="5538">In summary, the evidence that both AB-SOD and CHX-SOD reduce VAP incidence in ICU patients is accumulating. The optimal frequency and concentration for CHX-SOD remains to be demonstrated. From Scannapieco and colleagues' study we can conclude that twice daily is not necessarily better than once daily, but maybe a four times daily regimen with 2% instead of 0.12% CHX does make a difference. What we need now are well-designed and adequately powered studies to evaluate the effects of these measures on length of ICU stay and survival. If these effects were demonstrated, CHX-SOD would offer a very cheap and (ecologically) safe infection prevention measure in patient populations increasingly suffering from infections caused by AMRB.</offsets></p></sec><sec><title><offsets xml_i="8870" xml_f="8883" txt_i="5540" txt_f="5553">Abbreviations</offsets></title><p><offsets xml_i="8894" xml_f="9109" txt_i="5554" txt_f="5769">AB: antibiotics; AMRB: antimicrobial-resistant bacteria; CHX: chlorhexidine; SDD: selective decontamination of the digestive tract; SOD: selective oropharyngeal decontamination; VAP: ventilator-associated pneumonia.</offsets></p></sec><sec><title><offsets xml_i="9131" xml_f="9150" txt_i="5771" txt_f="5790">Competing interests</offsets></title><p><offsets xml_i="9161" xml_f="9219" txt_i="5791" txt_f="5849">The authors declare that they have no competing interests.</offsets></p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Scannapieco</surname><given-names>FA</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Raghavendran</surname><given-names>K</given-names></name><name><surname>Vacanti</surname><given-names>A</given-names></name><name><surname>Owens</surname><given-names>SI</given-names></name><name><surname>Wood</surname><given-names>K</given-names></name><name><surname>Mylotte</surname><given-names>JM</given-names></name><article-title>A randomized trial of chlorhexidine gluconate on oral bacterial pathogens in mechanically ventilated patients</article-title><source>Crit Care</source><year>2009</year><volume>13</volume><fpage>R117</fpage><pub-id pub-id-type="doi">10.1186/cc7967</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Chan</surname><given-names>EY</given-names></name><name><surname>Ruest</surname><given-names>A</given-names></name><name><surname>Meade</surname><given-names>MO</given-names></name><name><surname>Cook</surname><given-names>DJ</given-names></name><article-title>Oral decontamination for prevention of pneumonia in mechanically ventilated adults: systematic review and meta-analysis</article-title><source>BMJ</source><year>2007</year><volume>334</volume><fpage>889</fpage><pub-id pub-id-type="pmid">17387118</pub-id><pub-id pub-id-type="doi">10.1136/bmj.39136.528160.BE</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Bonten</surname><given-names>MJ</given-names></name><name><surname>Bergmans</surname><given-names>DC</given-names></name><name><surname>Ambergen</surname><given-names>AW</given-names></name><name><surname>de Leeuw</surname><given-names>PW</given-names></name><name><surname>Geest</surname><given-names>S van der</given-names></name><name><surname>Stobberingh</surname><given-names>EE</given-names></name><name><surname>Gaillard</surname><given-names>CA</given-names></name><article-title>Risk factors for pneumonia, and colonization of respiratory tract and stomach in mechanically ventilated ICU patients</article-title><source>Am J Respir Crit Care Med</source><year>1996</year><volume>154</volume><fpage>1339</fpage><lpage>1346</lpage><pub-id pub-id-type="pmid">8912745</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Bergmans</surname><given-names>DC</given-names></name><name><surname>Bonten</surname><given-names>MJ</given-names></name><name><surname>Gaillard</surname><given-names>CA</given-names></name><name><surname>Paling</surname><given-names>JC</given-names></name><name><surname>Geest</surname><given-names>S van der</given-names></name><name><surname>van Tiel</surname><given-names>FH</given-names></name><name><surname>Beysens</surname><given-names>AJ</given-names></name><name><surname>de Leeuw</surname><given-names>PW</given-names></name><name><surname>Stobberingh</surname><given-names>EE</given-names></name><article-title>Prevention of ventilator-associated pneumonia by oral decontamination: a prospective, randomized, double-blind, placebo-controlled study</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>382</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">11500337</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Pugin</surname><given-names>J</given-names></name><name><surname>Auckenthaler</surname><given-names>R</given-names></name><name><surname>Lew</surname><given-names>DP</given-names></name><name><surname>Suter</surname><given-names>PM</given-names></name><article-title>Oropharyngeal decontamination decreases incidence of ventilator-associated pneumonia. A randomized, placebo-controlled, double-blind clinical trial</article-title><source>JAMA</source><year>1991</year><volume>265</volume><fpage>2704</fpage><lpage>2710</lpage><pub-id pub-id-type="pmid">2023353</pub-id><pub-id pub-id-type="doi">10.1001/jama.265.20.2704</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>RodrÃ­guez-RoldÃ¡n</surname><given-names>JM</given-names></name><name><surname>Altuna-Cuesta</surname><given-names>A</given-names></name><name><surname>LÃ³pez</surname><given-names>A</given-names></name><name><surname>Carrillo</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>J</given-names></name><name><surname>LeÃ³n</surname><given-names>J</given-names></name><name><surname>MartÃ­nez-PellÃºs</surname><given-names>AJ</given-names></name><article-title>Prevention of nosocomial lung infection in ventilated patients: use of an antimicrobial pharyngeal nonabsorbable paste</article-title><source>Crit Care Med</source><year>1990</year><volume>18</volume><fpage>1239</fpage><lpage>1242</lpage><pub-id pub-id-type="pmid">2225893</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>de Smet</surname><given-names>AM</given-names></name><name><surname>Kluytmans</surname><given-names>JA</given-names></name><name><surname>Cooper</surname><given-names>BS</given-names></name><name><surname>Mascini</surname><given-names>EM</given-names></name><name><surname>Benus</surname><given-names>RF</given-names></name><name><surname>Werf</surname><given-names>TS van der</given-names></name><name><surname>Hoeven</surname><given-names>JG van der</given-names></name><name><surname>Pickkers</surname><given-names>P</given-names></name><name><surname>Bogaers-Hofman</surname><given-names>D</given-names></name><name><surname>Meer</surname><given-names>NJ van der</given-names></name><name><surname>Bernards</surname><given-names>AT</given-names></name><name><surname>Kuijper</surname><given-names>EJ</given-names></name><name><surname>Joore</surname><given-names>JC</given-names></name><name><surname>Leverstein-van sHall</surname><given-names>MA</given-names></name><name><surname>Bindels</surname><given-names>AJ</given-names></name><name><surname>Jansz</surname><given-names>AR</given-names></name><name><surname>Wesselink</surname><given-names>RM</given-names></name><name><surname>de Jongh</surname><given-names>BM</given-names></name><name><surname>Dennesen</surname><given-names>PJ</given-names></name><name><surname>van Asselt</surname><given-names>GJ</given-names></name><name><surname>te Velde</surname><given-names>LF</given-names></name><name><surname>Frenay</surname><given-names>IH</given-names></name><name><surname>Kaasjager</surname><given-names>K</given-names></name><name><surname>Bosch</surname><given-names>FH</given-names></name><name><surname>van Iterson</surname><given-names>M</given-names></name><name><surname>Thijsen</surname><given-names>SF</given-names></name><name><surname>Kluge</surname><given-names>GH</given-names></name><name><surname>Pauw</surname><given-names>W</given-names></name><name><surname>de Vries</surname><given-names>JW</given-names></name><name><surname>Kaan</surname><given-names>JA</given-names></name><article-title>Decontamination of the digestive tract and oropharynx in ICU patients</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>20</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">19118302</pub-id><pub-id pub-id-type="doi">10.1056/NEJMoa0800394</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>DeRiso</surname><given-names>AJ</given-names></name><name><surname>Ladowski</surname><given-names>JS</given-names></name><name><surname>Dillon</surname><given-names>TA</given-names></name><name><surname>Justice</surname><given-names>JW</given-names></name><name><surname>Peterson</surname><given-names>AC</given-names></name><article-title>Chlorhexidine gluconate 0.12% oral rinse reduces the incidence of total nosocomial respiratory infection and nonprophylactic systemic antibiotic use in patients undergoing heart surgery</article-title><source>Chest</source><year>1996</year><volume>109</volume><fpage>1556</fpage><lpage>1561</lpage><pub-id pub-id-type="pmid">8769511</pub-id><pub-id pub-id-type="doi">10.1378/chest.109.6.1556</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Fourrier</surname><given-names>F</given-names></name><name><surname>Cau-Pottier</surname><given-names>E</given-names></name><name><surname>Boutigny</surname><given-names>H</given-names></name><name><surname>Roussel-Delvallez</surname><given-names>M</given-names></name><name><surname>Jourdain</surname><given-names>M</given-names></name><name><surname>Chopin</surname><given-names>C</given-names></name><article-title>Effects of dental plaque antiseptic decontamination on bacterial colonization and nosocomial infections in critically ill patients</article-title><source>Intensive Care Med</source><year>2000</year><volume>26</volume><fpage>1239</fpage><lpage>1247</lpage><pub-id pub-id-type="pmid">11089748</pub-id><pub-id pub-id-type="doi">10.1007/s001340000585</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Genuit</surname><given-names>T</given-names></name><name><surname>Bochicchio</surname><given-names>G</given-names></name><name><surname>Napolitano</surname><given-names>LM</given-names></name><name><surname>McCarter</surname><given-names>RJ</given-names></name><name><surname>Roghman</surname><given-names>MC</given-names></name><article-title>Prophylactic chlorhexidine oral rinse decreases ventilator-associated pneumonia in surgical ICU patients</article-title><source>Surg Infect (Larchmt)</source><year>2001</year><volume>2</volume><fpage>5</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">12594876</pub-id><pub-id pub-id-type="doi">10.1089/109629601750185316</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Houston</surname><given-names>S</given-names></name><name><surname>Hougland</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>JJ</given-names></name><name><surname>LaRocco</surname><given-names>M</given-names></name><name><surname>Kennedy</surname><given-names>V</given-names></name><name><surname>Gentry</surname><given-names>LO</given-names></name><article-title>Effectiveness of 0.12% chlorhexidine gluconate oral rinse in reducing prevalence of nosocomial pneumonia in patients undergoing heart surgery</article-title><source>Am J Crit Care</source><year>2002</year><volume>11</volume><fpage>567</fpage><lpage>570</lpage><pub-id pub-id-type="pmid">12425407</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Koeman</surname><given-names>M</given-names></name><name><surname>Ven</surname><given-names>AJ van der</given-names></name><name><surname>Hak</surname><given-names>E</given-names></name><name><surname>Joore</surname><given-names>HC</given-names></name><name><surname>Kaasjager</surname><given-names>K</given-names></name><name><surname>de Smet</surname><given-names>AG</given-names></name><name><surname>Ramsay</surname><given-names>G</given-names></name><name><surname>Dormans</surname><given-names>TP</given-names></name><name><surname>Aarts</surname><given-names>LP</given-names></name><name><surname>de Bel</surname><given-names>EE</given-names></name><name><surname>Hustinx</surname><given-names>WN</given-names></name><name><surname>Tweel</surname><given-names>I van der</given-names></name><name><surname>Hoepelman</surname><given-names>AM</given-names></name><name><surname>Bonten</surname><given-names>MJ</given-names></name><article-title>Oral decontamination with chlorhexidine reduces the incidence of ventilator-associated pneumonia</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><fpage>1348</fpage><lpage>1355</lpage><pub-id pub-id-type="pmid">16603609</pub-id><pub-id pub-id-type="doi">10.1164/rccm.200505-820OC</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Segers</surname><given-names>P</given-names></name><name><surname>Speekenbrink</surname><given-names>RG</given-names></name><name><surname>Ubbink</surname><given-names>DT</given-names></name><name><surname>van Ogtrop</surname><given-names>ML</given-names></name><name><surname>de Mol</surname><given-names>BA</given-names></name><article-title>Prevention of nosocomial infection in cardiac surgery by decontamination of the nasopharynx and oropharynx with chlorhexidine gluconate: a randomized controlled trial</article-title><source>JAMA</source><year>2006</year><volume>296</volume><fpage>2460</fpage><lpage>2466</lpage><pub-id pub-id-type="pmid">17119142</pub-id><pub-id pub-id-type="doi">10.1001/jama.296.20.2460</pub-id></mixed-citation></ref></ref-list></back></article>